In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-associated Steatotic Liver Disease

被引:0
|
作者
Bao, Qinglan [1 ]
Zhang, Xiaoxiao [2 ]
Chen, Yingsong [1 ,3 ,4 ]
Wang, Tegexibaiyin [5 ]
Siqin, Bateer [6 ]
机构
[1] Inner Mongolia Med Univ, Hohhot, Peoples R China
[2] Xilin Gol League Mongolian Med Hosp, Xilingol Leagu, Peoples R China
[3] National&local Joint Mongolian Med R&D Engn Ctr, Tongliao, Peoples R China
[4] Inner Mongolia Minzu Univ, Tongliao, Peoples R China
[5] Affiliated Hosp Inner Mongolia Minzu Univ, Tongliao, Peoples R China
[6] Tradit Chinese & Mongolian Med Res Inst Inner Mong, Hohhot, Peoples R China
来源
关键词
ACID-INDUCED STEATOSIS; DIAGNOSIS; DIET;
D O I
10.3791/66810
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) has surged due to changes in economic and lifestyle patterns, leading to significant health challenges. Previous reports have studied the establishment of animal and cellular models for MASLD, highlighting differences between them. In this study, a cellular model was created by inducing fat accumulation in MASLD. HepG2 cells were stimulated with the unsaturated fatty acid oleic acid at various concentrations (0.125 mM, 0.25 mM, 0.5 mM, 1 mM) to emulate MASLD. The model's efficacy was assessed using cell counting kit-8 assays, Oil Red O staining, and lipid content analysis. This study aimed to create a simple-to-operate cellular model for MASLD cells. Results from the cell counting kit-8 assays showed that the survival of HepG2 cells was dependent on the concentration of oleic acid, with a GI50 of 1.875 mM. Cell viability in the 0.5 mM and 1 mM groups were significantly lower than those in the control group (P < 0.05). Furthermore, Oil Red O staining and lipid content analysis examined fat deposition at varying oleic acid concentrations (0.125 mM, 0.25 mM, 0.5 mM, 1 mM) on HepG2 cells. The lipid content of the 0.25 mM, 0.5 mM, and 1 mM groups was significantly higher than that of the control group (P < 0.05). Additionally, triglyceride levels in the OA groups were significantly higher than those in the control group (P < 0.05).
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease
    Gulati, Reeti
    Moylan, Cynthia A.
    Wilder, Julius
    Wegermann, Kara
    METABOLISM AND TARGET ORGAN DAMAGE, 2024, 4 (02):
  • [42] Metabolic Dysfunction-Associated Steatotic Liver Disease vs. Metabolic Dysfunction-Associated Fatty Liver Disease: Which Option is the Better Choice?
    Gambardella, Maria Luisa
    Abenavoli, Ludovico
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2025, 86 (02)
  • [43] Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology
    Portincasa, Piero
    Baffy, Gyorgy
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 124 : 35 - 39
  • [44] The liver-brain axis in metabolic dysfunction-associated steatotic liver disease
    Mikkelsen, Anne Catrine Daugaard
    Kjaergaard, Kristoffer
    Schapira, Anthony H. V.
    Mookerjee, Rajeshwar P.
    Thomsen, Karen Louise
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (03): : 248 - 258
  • [45] The gut-liver axis and metabolic dysfunction-associated steatotic liver disease
    Demir, Muenevver
    Tacke, Frank
    Mueller-Schilling, Martina
    Schmid, Stephan
    GASTROENTEROLOGIE, 2025,
  • [46] Metabolomic Hallmarks of Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Beyoglu, Diren
    Popov, Yury V.
    Idle, Jeffrey R.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (23)
  • [47] Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor
    Platek, Anna E.
    Szymanska, Anna
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 187 - 192
  • [48] flammation inhibitor for metabolic dysfunction-associated steatotic liver disease therapy
    Kang, Wang
    Zhang, Pengfei
    Sun, Huiyong
    Cui, Shuang
    Ao, Lanjia
    Cui, Ming
    Xu, Xiaowei
    Wang, Lin
    Xu, Yuanyuan
    Wang, Guangji
    Hong, Wang
    Haiping, Hao
    CHINESE JOURNAL OF NATURAL MEDICINES, 2024, 22 (11) : 965 - 976
  • [49] Metabolic dysfunction-associated steatotic liver disease and extrahepatic gastrointestinal cancers
    Mantovani, Alessandro
    Lonardo, Amedeo
    Stefan, Norbert
    Targher, Giovanni
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2024, 160
  • [50] Evolutionary aspects of metabolic dysfunction-associated steatotic liver disease (MASLD)
    Geier, Andreas
    Schiffels, Stephan
    Krawczyk, Marcin
    GASTROENTEROLOGIE, 2025,